Informational Booklet

HPV Awareness is a co-organizer and is on the scientific committee of an action plan that when implemented, will see significant results toward the elimination of cervical cancer not only in Canada but around the globe by the year 2030. Recognized top experts from across Canada (and beyond) came together to develop this important document complete with dozens of recommendations. (To be available soon).

Reports and Statements
  • Human Papillomavirus and Related Diseases in Canada. Summary Report 2015-03-20: Read Document
  • An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)†. Read Document
  • Healer of Cancer: The Power of the Mind, by Dr. Christian Boukaram: External Link
  • The HPV Vaccine Controversy, by Shobha S. Krishnan, M.D. External Link
  • Including males in Canadian human papillomavirus vaccination programs: a policy analysis.Read Document
  • Rebuttal: Do you approve of spending $300 million on HPV Vaccination?- Dr Marc Steben says yes.Read Document
  • Beliefs, behaviours and HPV vaccine: Correcting the myths and the misinformation Read Document
  • The Early Benefits of Human Papillomavirus Vaccination on Cervical Dysplasia and Anogenital Warts Read Document
  • Adverse events following immunization in Ontario’s female school-based HPV program Read Document
  • Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study Read Document
  • Are twenty human papillomavirus types causing cervical cancer? Read Document
  • Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes Read Document
  • Sex Differences Among College Students in Awareness of the HPV Vaccine and Vaccine Options Read Document
  • HPV vaccination: for women of all ages? Read Document
  • What is the responsibility of national government with respect to vaccination? Read Document
  • Financial Incentives for Increasing Uptake of HPV Vaccinations: A Randomized Controlled Trial Read Document
  • Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study Read Document
  • Indications for the HPV vaccine in adolescents: A review of the literature Read Document
  • The age of distribution of type-specific high-risk human papillomavirus incidence in two population-based screening trials Read Document
  • The Politics of HPV VAccination Advocacy: Effects of Source Expertise on Effectiveness of a Pro-Vaccine Message Read Document
  • Estimation of Geographic Variation in Human Papillomavirus Vaccine Uptake in Men and Women: An Online Survey Using Facebook Recruitment Read Document
  • Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study Read Document
  • Long-term Study of a Quadrivalent Human Papillomavirus Vaccine Read Document
  • Human Papillomavirus Vaccine Knowledge and Attitudes, Preventative Health Behaviors, and Medical Mistrust Among a Racially and Ethnically Diverse Sample of College Women Read Document
  • A risk for non-sexual transmission of human papillomavirus? Read Document
  • Immunisation against HPV in girls with intellectual disabilities Read Document
  • Implementation Science in Cancer Prevention and Control: A framework for research and programs in low and middle-income countries Read Document
  • Beta-Test Results for an HPV Information Web Site: Increasing HPV Vaccine Uptake in the United States Read Document
  • Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescent and young adults Read Document
  • Missed Opportunities for HPV Vaccination in Adolescent Girls: A Qualitative Study Read Document
  • Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study Read Document
  • Sex Is Like Jelly Beans: Educating Students on the Risks of Oral Sex Read Document
  • Primary care providers human papillomavirus vaccine recommendations for the medically underserved: A pilot study in U.S. Federally Qualified Health Centers Read Document
  • Early effects of human papillomavirus vaccination in Belgium Read Document
  • Co-infection with HPV types from the same species provides natural cross-protection from progression to cervical cancer Read Document
  • HPV Test Information. Read Document
HPV vaccination Gardasil®
  • Product Monograph, Gardasil® [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine] Suspension for injection, Active Immunizing Agent: Read Document
  • Part III: Consumer Information, Gardasil® [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine]: Read Document
HPV vaccination Gardasil® 9
  • Product Monograph, Gardasil® 9 [Human Papillomavirus 9-valent Vaccine, Recombinant] Suspension for injection, Active Immunizing Agent: Read Document
  • Part III: Consumer Information, Gardasil® 9 [Human Papillomavirus 9-valent Vaccine, Recombinant]: Read Document
HPV vaccination Cervarix®
  • Health Canada approves CERVARIX™, new GSK cervical cancer vaccine: Read Document
  • Product Monograph, Cervarix®[Human Papillomavirus vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted)] Suspension for injection, Active Immunizing Agent. ATC code: J07BM02: Read Document